Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Rating of “Moderate Buy” by Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $122.50.

A number of equities analysts have commented on LNTH shares. JMP Securities dropped their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Truist Financial restated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company.

Institutional Investors Weigh In On Lantheus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC lifted its holdings in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares in the last quarter. Silverberg Bernstein Capital Management LLC increased its position in Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after purchasing an additional 100 shares during the period. UMB Bank n.a. increased its position in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares during the period. GAMMA Investing LLC increased its position in Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares during the period. Finally, Moody National Bank Trust Division increased its position in Lantheus by 1.1% during the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after purchasing an additional 162 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 3.7 %

Shares of NASDAQ:LNTH opened at $90.52 on Monday. Lantheus has a 52 week low of $50.20 and a 52 week high of $126.89. The stock has a market capitalization of $6.29 billion, a P/E ratio of 15.06 and a beta of 0.51. The firm has a fifty day simple moving average of $103.13 and a two-hundred day simple moving average of $96.93.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.